Friday, September 18, 2020 3:09:30 PM
https://www.biospace.com/article/releases/nanoviricides-has-received-favorable-fda-comments-on-its-pre-ind-application-for-the-lead-drug-candidate/
I think it was you who recently posted that someone would be crazy not to have a pre-IND meeting with the FDA. That is true, but only with the added context, that is usually assumed: one should request the meeting to be held at the most strategically advantageous time during the completion of the IND package.
The FDA will grant a Pre-IND meeting at any time. You only get one such meeting, so legitimate drug developers choose the timing pretty carefully, to get the most out of it. In this case, NNVC had their pre-IND meeting without having completed any of the GPL-required tox studies, which is the least useful of all possible times to have this meeting.
They hadn't even PR'd the selection of a lead candidate prior to this one about the pre-IND meeting, which makes their comments about their "lead candidate" somewhat unbelievable.
Obviously, that meeting was for show to pump the stock, rather than for actually developing a lead. (assuming that actually did have that meeting).
Also, the FDA doesn't hand out random advice, or give "favorable comments", during pre-IND meetings, as reported by NNVC. The applicant provides data, and ask the FDA questions, to which the FDA replies. All that NNVC could have accomplished in their meeting would have been a theoretical discussion, showing the FDA their development plan, and asking "is this okay"? To which the FDA would have answered "Yes" if it was a standard plan. Thus, perhaps, a "favorable comment", and the lack of any need to really have selected a lead candidate.
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM